Has Cher Jacobsen received payments from drug or device companies?

Yes. Drug and device makers reported $4,475 in general payments to Cher Jacobsen across 309 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Cher Jacobsen did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Cher Jacobsen come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Cher Jacobsen

Family Medicine · Post Falls, IDNPI 1427102938

Payments from drug & device makers

$4,475in general payments, 2019–2025

Across 309 payments — averaging $14.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$971
AstraZeneca$870
Amgen$736
Johnson & Johnson$283
Novartis$244
Abbott$238
plus $1K from 15 others

What the payments were for

Food & beverage$4,36998%
Education$1062%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	117	$971
AstraZeneca(2 entities)	11	$870
Amgen	69	$736
Johnson & Johnson(2 entities)	15	$283
Novartis	16	$244
Abbott	12	$238
Pfizer	31	$207
Lilly USA, LLC	13	$172
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$153
Ascendis Pharma Endocrinology Inc	3	$145
Mayne Pharma Commercial LLC	2	$90
Novo Nordisk	2	$84
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$60
Axsome Therapeutics, Inc.	1	$59
Sumitomo Pharma America, Inc.	5	$51
Acadia Pharmaceuticals Inc	1	$40
Bayer	1	$20
Strongbridge US Inc.	1	$16
Otsuka America Pharmaceutical, Inc.	1	$15
Merck	1	$14
Phathom Pharmaceuticals, Inc.	1	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,475 in reported general payments places this provider in the 90th percentile of 803 family medicine providers in Idaho.

See all family medicine providers in Idaho →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	131	$123,777
JardianceEmpagliflozin	42	$49,087
MounjaroTirzepatide	36	$37,616
FarxigaDapagliflozin Propanediol	21	$27,728
Xigduo XrDapaglifloz Propaned/Metformin	27	$20,167
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	19	$19,942
RexultiBrexpiprazole	13	$18,453
Synjardy XrEmpagliflozin/Metformin Hcl	20	$18,446
Repatha SureclickEvolocumab	30	$16,008
EliquisApixaban	14	$14,764
Tresiba Flextouch U-200Insulin Degludec	18	$11,959
Soliqua 100-33Insulin Glargine/Lixisenatide	13	$11,728
TrulicityDulaglutide	12	$10,925
GemtesaVibegron	17	$9,402
Rosuvastatin Calcium	297	$4,240

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic	$84	$123,777131 claims
Lilly USA, LLCMounjaro, Trulicity	$172	$48,54148 claims
AstraZenecaFarxiga	$870	$27,72821 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$15	$18,45313 claims
PfizerEliquis	$207	$14,76414 claims
Sumitomo Pharma America, Inc.Gemtesa	$51	$9,40217 claims
AbbVieSynthroid	$971	$58612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 803 family medicine providers in Idaho.